Which is better, GSK or JNJ?

On the Buffett-Fit framework, Johnson & Johnson (JNJ) currently grades higher than GSK, 60/100 (C grade) vs 58/100 (C). That said, "better" depends on which framework you trust, GSK wins on Philip Fisher, Charlie Munger, and Terry Smith; JNJ wins on Warren Buffett, Benjamin Graham, Peter Lynch, and Joel Greenblatt. The full pillar breakdown is on this page.

Should I buy GSK or JNJ?

This page is an educational comparison, not investment advice. Both GSK and JNJ are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most, and always do your own research before making any investment decision.

Is GSK better than JNJ for value investing?

The two are close on the headline Buffett-Fit score (58/100 vs 60/100), so "better for value investing" depends on which pillar you weight most. The five Buffett pillars + six other frameworks are broken down side-by-side on this page so you can pick the one that fits your style.

What's the difference between GSK and JNJ on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). GSK currently scores 58/100; JNJ scores 60/100. The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, GSK or JNJ?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. GSK and JNJ are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, GSK or JNJ?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are GSK and JNJ both Healthcare stocks?

Yes: both GSK plc (GSK) and Johnson & Johnson (JNJ) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this GSK vs JNJ comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria: they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.